• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
CD39 is highly involved in mediating the suppression activity of tumor-infiltrating CD8+ T regulatory lymphocytes.CD39 高度参与调节肿瘤浸润 CD8+T 调节性淋巴细胞的抑制活性。
Cancer Immunol Immunother. 2013 May;62(5):851-62. doi: 10.1007/s00262-013-1392-z. Epub 2013 Jan 29.
2
CD39 is involved in mediating suppression by Mycobacterium bovis BCG-activated human CD8(+) CD39(+) regulatory T cells.CD39 参与调节由牛型结核分枝杆菌 BCG 激活的人 CD8(+) CD39(+)调节性 T 细胞的抑制作用。
Eur J Immunol. 2013 Jul;43(7):1925-32. doi: 10.1002/eji.201243286. Epub 2013 May 29.
3
IL-12 and IL-4 activate a CD39-dependent intrinsic peripheral tolerance mechanism in CD8(+) T cells.白细胞介素-12和白细胞介素-4激活CD8(+) T细胞中一种依赖CD39的内在外周耐受机制。
Eur J Immunol. 2016 Jun;46(6):1438-48. doi: 10.1002/eji.201545939. Epub 2016 Apr 8.
4
CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8 T Cells.CD39 表达定义了肿瘤浸润 CD8 T 细胞中的细胞耗竭。
Cancer Res. 2018 Jan 1;78(1):115-128. doi: 10.1158/0008-5472.CAN-16-2684. Epub 2017 Oct 24.
5
Evaluation of CD4 CD25 CD39 T-cell populations in peripheral blood of patients following kidney transplantation and during acute allograft rejection.肾移植患者外周血及急性移植物排斥反应期间CD4 CD25 CD39 T细胞群体的评估。
Nephrology (Carlton). 2017 Jul;22(7):505-512. doi: 10.1111/nep.12894.
6
Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients.肿瘤内调节性 T 细胞上调头颈部癌症患者的免疫抑制分子。
Br J Cancer. 2013 Nov 12;109(10):2629-35. doi: 10.1038/bjc.2013.645. Epub 2013 Oct 29.
7
Overexpression of PD-1 and CD39 in tumor-infiltrating lymphocytes compared with peripheral blood lymphocytes in triple-negative breast cancer.在三阴性乳腺癌中，肿瘤浸润淋巴细胞中 PD-1 和 CD39 的表达高于外周血淋巴细胞。
PLoS One. 2022 Jan 20;17(1):e0262650. doi: 10.1371/journal.pone.0262650. eCollection 2022.
8
Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas.细胞外酶 CD39 和 CD73 的协同作用导致人恶性脑胶质瘤中的腺苷能免疫抑制。
Neuro Oncol. 2013 Sep;15(9):1160-72. doi: 10.1093/neuonc/not067. Epub 2013 Jun 4.
9
Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients.癌症患者中 CD4+ CD39+ FOXP3+ 和 CD4+ CD39+ FOXP3neg T 细胞亚群的表型和功能特征。
Eur J Immunol. 2012 Jul;42(7):1876-85. doi: 10.1002/eji.201142347. Epub 2012 Jun 18.
10
Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine-mediated T cell hyporesponsiveness.人滤泡性淋巴瘤中CD39+浸润性T细胞促成腺苷介导的T细胞低反应性。
J Immunol. 2009 Nov 15;183(10):6157-66. doi: 10.4049/jimmunol.0900475. Epub 2009 Oct 28.

引用本文的文献

1
Exploring risk factors for autoimmune diseases complicated by non-hodgkin lymphoma through regulatory T cell immune-related traits: a Mendelian randomization study.通过调节性 T 细胞免疫相关特征探讨自身免疫性疾病并发非霍奇金淋巴瘤的危险因素：一项孟德尔随机研究。
Front Immunol. 2024 May 28;15:1374938. doi: 10.3389/fimmu.2024.1374938. eCollection 2024.
2
Identification of clinically relevant subsets CD39PD-1CD8 T cells and CD39 regulatory T cells in intrahepatic cholangiocarcinoma using single-cell CyTOF.使用单细胞质谱流式细胞术鉴定肝内胆管癌中临床相关的亚群CD39⁺PD-1⁺CD8⁺ T细胞和CD39⁺调节性T细胞
Transl Oncol. 2024 Jun;44:101954. doi: 10.1016/j.tranon.2024.101954. Epub 2024 Apr 11.
3
Altered CD39 and CD73 Expression in Rheumatoid Arthritis: Implications for Disease Activity and Treatment Response.类风湿关节炎中CD39和CD73表达的改变：对疾病活动度和治疗反应的影响
Biomolecules. 2023 Dec 19;14(1):1. doi: 10.3390/biom14010001.
4
Antigen-specific decidual CD8+ T cells include distinct effector memory and tissue-resident memory cells.抗原特异性蜕膜 CD8+T 细胞包括不同的效应记忆细胞和组织驻留记忆细胞。
JCI Insight. 2023 Sep 8;8(17):e171806. doi: 10.1172/jci.insight.171806.
5
Location of CD39 T cell subpopulations within tumors predict differential outcomes in non-small cell lung cancer.肿瘤内 CD39 T 细胞亚群的位置预测非小细胞肺癌的不同预后。
J Immunother Cancer. 2023 Aug;11(8). doi: 10.1136/jitc-2023-006770.
6
Review immune response of targeting CD39 in cancer.综述癌症中靶向CD39的免疫反应。
Biomark Res. 2023 Jun 7;11(1):63. doi: 10.1186/s40364-023-00500-w.
7
Improving combination therapies: targeting A2B-adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression.改善联合治疗策略：靶向 A2B- 腺苷受体调节代谢肿瘤微环境和免疫抑制。
J Natl Cancer Inst. 2023 Nov 8;115(11):1404-1419. doi: 10.1093/jnci/djad091.
8
Learning from the nexus of autoimmunity and cancer.从自身免疫与癌症的联系中学习。
Immunity. 2023 Feb 14;56(2):256-271. doi: 10.1016/j.immuni.2023.01.022.
9
Colorectal Cancer and Purinergic Signalling: An Overview.结直肠癌与嘌呤能信号传导：综述
Cancers (Basel). 2022 Oct 6;14(19):4887. doi: 10.3390/cancers14194887.
10
Overexpression of PD-1 and CD39 in tumor-infiltrating lymphocytes compared with peripheral blood lymphocytes in triple-negative breast cancer.在三阴性乳腺癌中，肿瘤浸润淋巴细胞中 PD-1 和 CD39 的表达高于外周血淋巴细胞。
PLoS One. 2022 Jan 20;17(1):e0262650. doi: 10.1371/journal.pone.0262650. eCollection 2022.

本文引用的文献

1
Regulation of self-tolerance by Qa-1-restricted CD8(+) regulatory T cells.Qa-1 限制的 CD8(+)调节性 T 细胞对自身耐受的调节。
Semin Immunol. 2011 Dec;23(6):446-52. doi: 10.1016/j.smim.2011.06.001.
2
Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis.CCR6-CCL20 通过选择性招募调节性 T 细胞促进肝癌进展并预示不良预后。
PLoS One. 2011;6(9):e24671. doi: 10.1371/journal.pone.0024671. Epub 2011 Sep 14.
3
Regulatory T cells in gastrointestinal tumors.胃肠道肿瘤中的调节性 T 细胞。
Expert Rev Gastroenterol Hepatol. 2011 Aug;5(4):489-501. doi: 10.1586/egh.11.44.
4
Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells.FOXP3 表达在非小细胞肺癌细胞与肿瘤浸润调节性 T 细胞中的预后潜能。
Lung Cancer. 2012 Jan;75(1):95-101. doi: 10.1016/j.lungcan.2011.06.002. Epub 2011 Jun 29.
5
CD8⁺ cytotoxic T cell and FOXP3⁺ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes.CD8⁺ 细胞毒性 T 细胞和 FOXP3⁺ 调节性 T 细胞浸润与乳腺癌生存和分子亚型的关系。
Breast Cancer Res Treat. 2011 Nov;130(2):645-55. doi: 10.1007/s10549-011-1647-3. Epub 2011 Jun 30.
6
Targeting human inducible regulatory T cells (Tr1) in patients with cancer: blocking of adenosine-prostaglandin E₂ cooperation.针对癌症患者的人诱导调节性 T 细胞（Tr1）：阻断腺苷-前列腺素 E₂ 协同作用。
Expert Opin Biol Ther. 2011 Sep;11(9):1203-14. doi: 10.1517/14712598.2011.581225. Epub 2011 Jun 26.
7
Impact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancer.CD39 和嘌呤能信号对结直肠癌生长和转移的影响。
Purinergic Signal. 2011 Jun;7(2):231-41. doi: 10.1007/s11302-011-9228-9. Epub 2011 Apr 2.
8
Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma.外周血和肿瘤浸润淋巴细胞中调节性 T 细胞的频率与肾细胞癌的预后不良相关。
BJU Int. 2011 May;107(9):1500-6. doi: 10.1111/j.1464-410X.2010.09555.x. Epub 2010 Aug 24.
9
CD8(+) T regulatory/suppressor cells and their relationships with autoreactivity and autoimmunity.CD8(+) T 调节/抑制细胞及其与自身反应性和自身免疫的关系。
Autoimmunity. 2011 Feb;44(1):51-7. doi: 10.3109/08916931003782171. Epub 2010 Jul 29.
10
Extracellular adenosine triphosphate and adenosine in cancer.细胞外三磷酸腺苷和腺苷在癌症中的作用。
Oncogene. 2010 Sep 30;29(39):5346-58. doi: 10.1038/onc.2010.292. Epub 2010 Jul 26.

CD39 高度参与调节肿瘤浸润 CD8+T 调节性淋巴细胞的抑制活性。

CD39 is highly involved in mediating the suppression activity of tumor-infiltrating CD8+ T regulatory lymphocytes.

机构信息

Centre of Excellence for Biomedical Research, University of Genoa, Viale Benedetto XV n. 7, 16132, Genoa, Italy.

出版信息

Cancer Immunol Immunother. 2013 May;62(5):851-62. doi: 10.1007/s00262-013-1392-z. Epub 2013 Jan 29.

DOI:10.1007/s00262-013-1392-z
PMID:23359087
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11029015/
Abstract

CD39 is an ectoenzyme, present on different immune cell subsets, which mediates immunosuppressive functions catalyzing ATP degradation. It is not known whether CD39 is expressed and implicated in the activity of CD8+ regulatory T lymphocytes (Treg). In this study, CD39 expression and function was analyzed in both CD8+ and CD4+CD25(hi) Treg from the peripheral blood of healthy donors as well as from tumor specimens. CD39 was found expressed by both CD8+ (from the majority of healthy donors and tumor patients) and CD4+CD25(hi) Treg, and CD39 expression correlated with suppression activity mediated by CD8+ Treg. Importantly, CD39 counteraction remarkably inhibited the suppression activity of CD8+ Treg (both from peripheral blood and tumor microenvironment) suggesting that CD39-mediated inhibition constitutes a prevalent hallmark of their function. Collectively, these findings, unveiling a new mechanism of action for CD8+ Treg, provide new knowledge on intratumoral molecular pathways related to tumor immune escape, which could be exploited in the future for designing new biological tools for anticancer immune intervention.

摘要

CD39 是一种存在于不同免疫细胞亚群上的细胞外酶，通过催化 ATP 降解来介导免疫抑制功能。目前尚不清楚 CD39 是否在 CD8+调节性 T 淋巴细胞（Treg）的活性中表达和发挥作用。在这项研究中，我们分析了来自健康供体和肿瘤标本的外周血中 CD8+和 CD4+CD25(hi)Treg 细胞中 CD39 的表达和功能。结果发现 CD39 在 CD8+（来自大多数健康供体和肿瘤患者）和 CD4+CD25(hi)Treg 细胞中均有表达，并且 CD39 的表达与 CD8+Treg 介导的抑制活性相关。重要的是，CD39 的拮抗作用显著抑制了 CD8+Treg（来自外周血和肿瘤微环境）的抑制活性，这表明 CD39 介导的抑制作用是其功能的一个普遍特征。总之，这些发现揭示了 CD8+Treg 的一种新的作用机制，为与肿瘤免疫逃逸相关的肿瘤内分子途径提供了新的知识，这可能为未来设计抗癌免疫干预的新生物工具提供了依据。